The biotech has been singled out for a $1.6bn payment for US Covid-19 vaccine development.
Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.
So far so good, as much of pharma shrugs off the full-year impact of Covid-19.
Covid-19 could mean Medtronic loses out to Abbott, its rival in the mitral valve space.
Launch phase is a challenging time for drug developers, so consider the likes of Biohaven, Esperion and, most recently, Urogen, as they brave locked-down markets.
Diagnostics prove defensive for Abbott, as the company jumps the FDA’s gun with its third coronavirus test.
From research collaborations to changes to drug development, pharma will have to find new ways of working to discover Covid-19 treatments.
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
Antivirals, anti-interleukins and vaccines take centre stage in clinical trial efforts to tackle the coronavirus pandemic.